These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21484248)

  • 1. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.
    Fukutomi A; Hatake K; Matsui K; Sakajiri S; Hirashima T; Tanii H; Kobayashi K; Yamamoto N
    Invest New Drugs; 2012 Jun; 30(3):1096-106. PubMed ID: 21484248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
    Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
    Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
    Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
    Shapiro GI; Frank R; Dandamudi UB; Hengelage T; Zhao L; Gazi L; Porro MG; Woo MM; Lewis LD
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):555-62. PubMed ID: 22057852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
    Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
    Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
    Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
    Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
    Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
    Hamberg P; Woo MM; Chen LC; Verweij J; Porro MG; Zhao L; Li W; van der Biessen D; Sharma S; Hengelage T; de Jonge M
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):805-13. PubMed ID: 21706316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
    Bauer S; Hilger RA; Mühlenberg T; Grabellus F; Nagarajah J; Hoiczyk M; Reichardt A; Ahrens M; Reichardt P; Grunewald S; Scheulen ME; Pustowka A; Bock E; Schuler M; Pink D
    Br J Cancer; 2014 Mar; 110(5):1155-62. PubMed ID: 24434430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
    Gray JE; Haura E; Chiappori A; Tanvetyanon T; Williams CC; Pinder-Schenck M; Kish JA; Kreahling J; Lush R; Neuger A; Tetteh L; Akar A; Zhao X; Schell MJ; Bepler G; Altiok S
    Clin Cancer Res; 2014 Mar; 20(6):1644-55. PubMed ID: 24429877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
    Ibrahim N; Buchbinder EI; Granter SR; Rodig SJ; Giobbie-Hurder A; Becerra C; Tsiaras A; Gjini E; Fisher DE; Hodi FS
    Cancer Med; 2016 Nov; 5(11):3041-3050. PubMed ID: 27748045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
    Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
    Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
    Thomas S; Aggarwal R; Jahan T; Ryan C; Troung T; Cripps AM; Raha P; Thurn KT; Chen S; Grabowsky JA; Park J; Hwang J; Daud A; Munster PN
    Ann Oncol; 2016 May; 27(5):947-52. PubMed ID: 26903311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
    Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
    Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
    Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.